Search Results
17 items found for "Shivani Sachdev"
- Ep 116 with Dr. Shivani Sachdev
Shivani Sachdev About Dr. Shivani Sachdev "Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr.
- Ep 116 with Dr. Shivani Sachdev
Shivani Sachdev "Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr.
- Replay Ep 116 with Dr. Shivani Sachdev
Shivani Sachdev About Dr. Shivani Sachdev "Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr.
- Replay Ep 116 with Dr. Shivani Sachdev
Shivani Sachdev "Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr.
- 23-05 Dr GPCR Newsletter
Our program includes talks from: Oliver Hartley Gaspar Pandy-Szekeres Ilana Kotliar Nicolas Gilles Shivani Sachdev Etienne Billard Sudha Shenoy Paul Gasser Stuart Maudsley Kaavya Krishna Kumar We have set aside Bruns , Paul Gasser , Shivani Sachdev and Pierre Eftekhari . Dr.
- 23-04 Dr GPCR Newsletter
Our program includes talks from: Oliver Hartley Gaspar Pandy-Szekeres Ilana Kotliar Nicolas Gilles Shivani Sachdev Etienne Billard Sudha Shenoy Paul Gasser Stuart Maudsley Kaavya Krishna Kumar We have set aside
- 24-01 Dr GPCR Newsletter
Shivani Sachdev as she talks about her career in the GPCR industry. Dr.
- 22-09 Dr GPCR Newsletter
2022: Hannes Schihada , The Philipp University of Marburg Carole Daly , Queen's University Belfast Shivani Sachdev , National Institutes of Health, NIDDK Gabriele Kockelkoren , University of Copenhagen Chloe determinants of ligand pharmacological activity on β2 adrenoceptor A Setmelanotide-like Effect at MC4R Is Achieved
- G Protein-coupled Receptor-mediated Membrane Targeting of PLCγ2 is Essential for Neutrophil Chemotaxis
by which PLCγ2 plays an essential role in neutrophil chemotaxis. " Authors Xuehua Xu , Xi Wen , Smit Bhimani
- GPCRs and fibroblast heterogeneity in fibroblast-associated diseases
focused target identification, polypharmacology, and effective personalized medicine approaches to achieve
- The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
A 28.6% reduction in maximum target lesion diameter was achieved when PRL3-zumab was administered concurrently
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
Twenty percent of the patients achieved complete remission, with or without hematologic count recovery
- LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration
Ultimately, complete inhibition of cell migration toward CXCL12 and alkyl-OMPT was only achieved in the
- Ep 107 with Dr. Roger Sunahara
is an important perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve
- Ep 107 with Dr. Roger Sunahara
is an important perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve
- 20-10 Dr GPCR Newsletter
Achievement of this milestone triggers a payment of $5 million to Sosei Heptares .